Based on this fact, ONTT can be regarded as a randomized controlled trial for the acute treatment of MS-ON and idiopathic ON (i.e., double-seronegative for MOG-IgG and AQP4-IgG). The gene discussed is AQP4; the disease is myeloid sarcoma.